Research Article

Fei Tu, Mengfan Li, Yinyu Chen, Huiru Chu, Shujie Wang, Lun Hai, Ting Xie, Fangfang Geng, Tiesuo Zhao, Qingzhi Wang*, Zhiwei Feng*

Let-7i-3p inhibits the cell cycle, proliferation, invasion, and migration of colorectal cancer cells via downregulating CCND1

https://doi.org/10.1515/med-2022-0499
received November 29, 2021; accepted May 15, 2022

Abstract: Dysregulated microRNAs are closely related to the malignant progression of colorectal cancer (CRC). Although abnormal let-7i-3p expression has been reported in various human cancers, its biological role and potential mechanism in CRC remain unclear. Therefore, the purpose of this study was to investigate the expression and regulation of let-7i-3p in CRC. Here, we demonstrated that let-7i-3p expression was significantly downregulated in three CRC cell lines while CyclinD1 (CCND1) was upregulated compared with the normal colon epithelial FHC cells. Moreover, bioinformatics and luciferase reporter assays revealed that CCND1 was a direct functional target of let-7i-3p. In addition, let-7i-3p overexpression or CCND1 silencing inhibited cell cycle, proliferation, invasion, and migration and diminished the activation of p-ERK in HCT116 cells. However, exogenously expressing CCND1 alleviated these effects. Taken together, our findings may provide new insight into the pathogenesis of CRC and let-7i-3p/CCND1 might function as new therapeutic targets for CRC.

Keywords: let-7i-3p, CCND1, proliferation, invasion, migration, colorectal cancer cells

1 Introduction

Colorectal cancer (CRC) poses a serious threat to human life and health as it is the third most common cancer in the world and the fourth leading cause of cancer death [1,2]. Patients with advanced colorectal cancer cannot receive surgical treatment due to the development of liver and lung metastases [3,4]. Therefore, it is necessary to elucidate the pathogenesis and potential molecular mechanisms of CRC tumor metastasis, which will help to find potential therapeutic targets for CRC.

MicroRNAs (miRNAs) are a class of endogenous regulatory non-coding RNAs found in eukaryotes with a length of about 20–25 nucleotides [5]. miRNAs can down-regulate the expression of target genes by inhibiting mRNA cleavage or translation repression [6,7]. In recent years, a large number of studies have shown that miRNAs are involved in a variety of cell processes, such as cell proliferation, invasion, migration, and cell cycle progression. For example, miR-BART10-3p regulates EBVaGC cell proliferation and migration by directly targeting DKK1 [8]. Transient activation of miR-294 leads to myocyte cell cycle reactivation [9]. Let-7i downregulates GREB1 to inhibit the progression of esophageal cancer [10]. Let-7i inhibits gastric cancer invasion and metastasis by targeting COL1A1 [11]. Interestingly, the microarray data of previous studies have shown that let-7i-3p levels are significantly reduced in CRC cell lines (SW620, LoVo) compared to normal colon epithelial FHC cells [12]. However, the molecular mechanisms and specific biological functions of let-7i-3p in CRC remain largely unknown.
Cyclin D1 is encoded by the CCND1 gene and is a promoter of the cell cycle, which is involved in the tumorigenesis of many cancers [13–15]. Previous studies have shown that high levels of CCND1 are associated with poor prognosis in CRC patients [16–18]. Therefore, understanding the regulatory mechanisms of CCND1 may help to develop strategies to combat colorectal cancer cell migration and invasion.

Based on the above considerations, this study aimed to investigate whether let-7i-3p regulates the cell cycle, proliferation, migration, and invasion of colorectal cancer cells by targeting CCND1.

2 Materials and methods

2.1 Cell lines and cell culture

The human colorectal cancer cell lines SW480, HCT116, LoVo, RKO, and HT29 and the normal colon epithelial cell lines FHC and 293T were obtained from the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, USA) containing 10% fetal bovine serum (FBS) and 1% antibiotics (100 U mL−1 penicillin and 100 mg mL−1 streptomycin). They were incubated in a humidified atmosphere at 37°C containing 5% CO2.

2.2 Oligonucleotide transfection

Let-7i-3p mimic (named as let-7i-3p), negative control duplex (named as NC), and siRNA against CCND1 (named as siCCND1) were synthesized by GenePharma (Shanghai, China) and were applied for transfection. Oligonucleotide transfection was performed using Lipofectamine 3000 reagents (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. The sequences are listed in Table 1.

2.3 RNA extractions and qRT-PCR

Total RNA was extracted from cells using the TRIzol reagent (Invitrogen, CA, USA) following the manufacturer’s protocol. Then, we used FastKing RT Kit (with gDNase) (TIANGEN, China) to synthesize cDNA. qRT-PCR was performed on a Quant Studio5 Real-time PCR System (Applied Biosystems, USA) with ChamQ™ Universal SYBR® qPCR Master Mix (Vazyme Biotech, Nanjing, China).

2.4 miRNA expression

miRNA expression was measured using miRNA Universal SYBR® qPCR Master Mix Assays (Vazyme Biotech, Nanjing, China). The reverse transcription reaction was performed with the miRNA 1st-Strand cDNA Synthesis Kit (by stem-loop) (Vazyme Biotech, Nanjing, China) according to the manufacturer’s protocol.

Table 1: Oligonucleotide sequences

| Namea | Sequence (5’–3’)b | Usage |
|-------|------------------|-------|
| let-7i-3p (sense) | CUGCGCAAGCUACUGCCUUUGCU | Transfection |
| NC (sense) | UUCUCCGAACGUUGCACGUTT | Transfection |
| siCCND1-1 (sense) | CGGUGAGGCCUGAAAGTTT | Transfection |
| siCCND1-2 (sense) | CCCAGUGAUCAAGUGUGATT | Transfection |
| U6-F | CTCGCTTGGCCAGCACA | qRT-PCR |
| U6-R | AACGCTTCAGAATTTTGT | qRT-PCR |
| CCND1-F | ATCAACTGTGACCGAGCTG | qRT-PCR |
| CCND1-R | CTTGGGTTCCATGTCTGCTT | qRT-PCR |
| let-7i-3p-R | GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGCAAG | RT |
| let-7i-3p-Q | CGCTGCAAGCTACTGC | qRT-PCR |
| GAPDH-F | AAATCCCATCACCATCTC | qRT-PCR |
| GAPDH-R | TCACACCCATGAGACAA | qRT-PCR |
| CCND1-wt-F | CCGGAGCTCTTCAACCCACAGCTACTTGG | Plasmid construction |
| CCND1-wt-R | CCCGTCGACTCAGATCTGCTGGGGAAACG | Plasmid construction |
| CCND1-mut-F | AGGCTGGTGAGGAATCTGCGGGCCGGGACACGGAGTCT | Mutagenesis |
| CCND1-mut-R | GCCAGTTCGCCACCAGCTTGGCCTCTCCATAC | Mutagenesis |
| CCND1-FL-F | CCGGATCTCATGGAACACGAGCCTCTTGTG | Plasmid construction |
| CCND1-FL-R | CCGTCTGAGTCAAGTCTCCACGCTCCG | Plasmid construction |

aF, forward primer; R, reverse primer.
bMutated target sites are underlined.
2.5 Plasmid construction and dual-luciferase assay

The fragment of the 3′-UTR of CCND1 containing the predicted let-7i-3p-binding site was amplified by PCR and inserted between the Sacl and Sall restriction sites of the pmirGLO Dual-Luciferase miRNA Target Expression Vector (kindly provided by Prof. Qifa Li of Nanjing Agricultural University, Nanjing, China). For mutation, the let-7i-3p-binding motif in the 3′-UTR of the CCND1 gene was mutated by using the Mut Express MultiS Fast Mutagenesis Kit V2 (Vazyme Biotech, Nanjing, China). Luciferase activity was measured 24 h after transfection using the Dual-Glo luciferase assay system (Promega, USA). Renilla luciferase activity served as the internal control. The CCND1 cDNA was amplified by PCR and cloned into the pcDNA3.1 (+) (kindly provided by Prof. Qifa Li of Nanjing Agricultural University, Nanjing, China). All of the constructs were verified by sequencing.

2.6 Western blot analysis

The cell pellets were harvested and re-suspended in lysis buffer (20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 25 mM β-glycerol-phosphate, 1 mM Na3VO4, 10% glycerol, 1× PMSF, with the sigma phosphatase inhibitors and protease inhibitor; Pierce, Rockford, IL, USA). The re-suspended cell pellet was then incubated on ice for 20 min, followed by centrifugation at 12,000×g for 20 min at 4°C. The supernatants were collected and protein concentrations were measured using the BCA Protein Assay Kit (Beyotime, Shanghai, China). Finally, cell lysates were subjected to western blot analysis of the following antibodies: CCND1 (CST, 5506S), α-tubulin (CST, 3873S), p-Erk1/2 (CST, 4370S), Erk1/2 (CST, 4695S), and GAPDH (protein-tech, 60004-1).

2.7 Cell proliferation assay

Cell Counting Kit-8 (CCK-8) (Beyotime, Shanghai, China) was used to measure the cell proliferation according to the manufacturer’s recommendations. Cells were transfected with let-7i-3p mimic or mimic NC, siCCND1, or pcDNA-CCND1 + let-7i-3p mimic. Forty-eight hours later, the transfected cells were trypsinized, counted, and replated at a density of 2000 cells/well in a 96-well plate, 10 μL of CCK-8 solution was added into the medium at different time points, and the absorbance (450 nm) was assessed on a SpectraMax iD3 Multi-Mode Microplate Reader (Molecular Devices, USA). All the experiments were performed at least three times, and the mean was calculated.

2.8 Colony formation assay

The transfected cells as described above were plated in a six-well plate (1,000 cells per well) and cultured with DMEM for about 2 weeks. Proliferating colonies resulting from the surviving cells were fixed with 3.7% methanol, stained with 0.1% crystal violet, and counted. Colonies containing at least 50 cells were scored. Each assay was performed in triplicate.

2.9 Cell cycle and apoptosis assays by flow cytometry

For cycle analysis, the test was performed using a cell cycle and apoptosis analysis kit (C1052; Beyotime, Shanghai, China). For apoptosis analysis, the test was performed using the Annexin-V-PE/7-AAD apoptosis detection kit (Vazyme Biotech, Nanjing, China). The transfected cells were harvested, washed, and stained according to the manufacturer’s protocol. Then, the stained cells were measured by CytoFLEX (Beckman Coulter, USA) and analyzed using FlowJo software version 7.6. Three independent assays were conducted.

2.10 Scratch wound-healing assay

A scratch wound-healing assay was performed for the analysis of cell migration. The transfected cells were incubated on six-well plates (3 × 104 cells per well) with 5% CO2 at 37°C. After 24 h, the plate was scratched using a pipette. Then, the cells were washed and incubated with fresh serum-free DMEM in the incubator and observed at 0 and 48 h. Images were acquired under an inverted microscope. Experiments were performed in triplicate.
2.11 Cell invasion assay

For the invasion assay, the transfected cells were put into the upper chamber of each well of a 24-well transwell polycarbonate membrane (8 μm pore size, millepore) coated with Matrigel (BD, USA). Medium containing 10% FBS, which served as a chemoattractant, was put into the lower chambers. After wells were incubated for 24 h at 37°C, the surface of cells on the upper membrane was removed. The cells were fixed and stained with 0.05% crystal violet. Six random fields of each chamber were photographed using an inverted microscope at 200× magnification. The mean of triplicate assays for each experimental condition was used.

2.12 Statistical analysis

All measurement data are represented as mean ± standard deviation. The statistical differences between groups were analyzed using t-tests of GraphPad Prism9. P-values were determined by paired-samples t-tests: *P < 0.05, **P < 0.01, and ***P < 0.001.

3 Results

3.1 Let-7i-3p is significantly downregulated but CCND1 upregulated in CRC cells

To verify whether let-7i-3p was abnormally expressed in CRC cells, we analyzed the expression level of let-7i-3p in three CRC cells (HCT116, SW480, and LoVo) and normal colon epithelial cell line (FHC) (Figure 1a). Consistent with the microarray data of previous reports [12], our qRT-PCR results showed that the expression of let-7i-3p in CRC cells was significantly reduced compared with
FHC cells. Considering that let-7i-3p mainly plays a role through its target genes, we screened potential target genes by RNAhybrid. Comprehensive data analysis and literature review predicted that CCND1 might be a putative target gene of let-7i-3p. To evaluate the relation between let-7i-3p and CCND1 expression levels in CRC, similarly, we detected CCND1 expression levels in three CRC cells and FHC. As shown in Figure 1b, the expression of CCND1 was upregulated in CRC cells compared with FHC cells. Next, CCND1 expression was detected in CRC cells and FHC by western blot. The results showed that the relative expression of CCND1 protein level in CRC cells (HCT116, SW480) was significantly upregulated compared with FHC cells (Figure 1c and d). These results further supported CCND1 as a potential target gene regulated by let-7i-3p.

3.3 CCND1 is a direct target of let-7i-3p

RNA-hybrid was used to analyze the potential let-7i-3p target gene. We constructed a dual-luciferase reporter plasmid recombined with either wild-type (WT) or mutant (MUT) type 3′-UTR of CCND1 (Figure 3a). The result showed that co-transfection of let-7i-3p significantly decreased the luciferase activity in HCT116 and 293T cells with WT 3′-UTR of CCND1 but not in those with MUT type (Figure 3b and c). To verify that CCND1 is the true downstream target of let-7i-3p, we examined the effect of the let-7i-3p expression on CCND1 expression by qRT-PCR and western blot. As shown in Figure 3d–f, let-7i-3p significantly suppressed both mRNA and protein expression levels of CCND1. These data suggested that CCND1 was a direct target of let-7i-3p.

3.4 Knockdown of CCND1 inhibits cell cycle, proliferation, migration, and invasion in HCT116

To investigate whether siCCND1 has a similar function to let-7i-3p in CRC cells, two siCCND1s were transfected into HCT116 cells. The silencing of CCND1s was confirmed by real-time RT-PCR and western blot. The result showed that the siCCND1s’ transfection of HCT116 cells efficiently knocked down CCND1 mRNA and protein expression (Figure 4a and c). To further explore the role of CCND1 in HCT116 cells, we analyzed the effect of siCCND1 in controlling cell proliferation, cell cycle, migration, and invasion. The results showed that the silencing of CCND1 led to the significant inhibition of proliferation, migration, and invasion, in a pattern similar to that of let-7i-3p overexpression (Figure 4d and l).

3.5 CCND1 overexpression reverses the effects of let-7i-3p on HCT116 cells

To confirm the function of CCND1 in CRC cells, we tested the effect of CCND1 overexpression on the cell cycle, proliferation, migration, and invasion. We ectopically expressed CCND1 together with let-7i-3p in HCT116 cells. qRT-PCR and western blot analyses showed that CCND1 mRNA and protein levels dramatically increased in pcDNA-CCND1-transfected HCT116 cells (Figure 5a and c). Furthermore, we performed CCK8 assay, colony-forming assay, flow
Figure 2: Let-7i-3p inhibits the cell cycle, proliferation, migration, and invasion but does not affect the apoptosis in HCT116. (a) The expressions of let-7i-3p were measured after transfecting let-7i-3p or NC into HCT116 cells. (b and c) Cell viability was determined by Annexin-V/7-AAD staining. Representative flow cytometric analysis of apoptosis (b) and statistical histogram was shown at right (c). (d) Relative cell cycle distribution detected by flow cytometry and statistical histogram was shown at right (e). (f) The effects of let-7i-3p mimics or NC on HCT116 cells’ proliferation as determined by CCK-8 assay. (g) A colony formation assay was used to detect the cell colony formation ability after the transfection of let-7i-3p in HCT116 cells and a statistical histogram was shown at right (h). (i) The effects of let-7i-3p mimics and NC on HCT116 cells’ invasion determined by transwell assay and statistical histogram was shown at right (j). (k) Images were acquired at 0 and 48 h after wounding. The percentage of the wound healing was calculated as (the width of wound at 0 h – the width of wound at 48 h)/the width of wound at 0 h and a statistical histogram was shown at right (l). *P < 0.05, **P < 0.01, and ***P < 0.001.
cytometry, transwell assay, and wound-healing migration assay in HCT116 cells. As expected, the results showed that there was no significant difference between the pcDNA-CCND1 + let-7i-3p group and the control group (Figure 5d and l). Taken together, these results displayed that let-7i-3p inhibited cell cycle, proliferation, migration, and invasion in HCT116 by targeting CCND1.

### 3.6 Let-7i-3p decreases the ERK signaling pathway by downregulation of CCND1

To examine the mechanisms of how let-7i-3p and CCND1 inhibited the cell cycle, proliferation, migration, and invasion in CRC, we investigated whether these effects were mediated by activating the ERK signaling pathway. Western blot was used to examine CCND1 expression levels and p-ERK. As shown in Figure 6a and c, overexpressed let-7i-3p caused a significant decrease in p-ERK in HCT116 cells by comparison to the control group. However, there was no significant difference in total-ERK expression. Similarly, the same results can be obtained by downregulating the CCND1 expression in HCT116 cells (Figure 6d and e). We ectopically expressed CCND1 in HCT116 cells that increased significantly the p-ERK compared to the control group (Figure 6f and g). These results suggested that CCND1 played a catalytic role in the ERK signaling pathway.

All these results suggested that CCND1 was a down-stream functional regulator of let-7i-3p through ERK signaling pathway.

### 4 Discussion

There are not many studies on let-7i-3p. Luo et al. reported that let-7i-3p inhibited the osteogenic differentiation of hASCs under cyclic strain in vitro acting as a negative regulator of the Wnt/β-catenin pathway by targeting Lef1 [19]. Sun et al. observed that low expression of let-7i-3p can enhance the osteoblast differentiation in ankylosing spondylitis (AS) mice by upregulating PDK1 [20]. Falzone et al. proved that let-7i-3p was associated with oral cancer recurrence [21]. Tang et al. reported that microarray data showed let-7i-3p levels significantly reduced in CRC cell lines (SW620, LoVo) compared to normal colon epithelial FHC cells [12]. However, there are few studies on the role of let-7i-3p in the pathogenesis of CRC.

In our study, we confirmed that the expression level of let-7i-3p in CRC cell lines (HCT116, SW480, and LoVo)
Figure 4: siCCND1 inhibits the proliferation, cell cycle, migration, and invasion of HCT116 cells. (a) qRT-PCR was used to detect the mRNA expression of CCND1 in siCCND1 and siNC. (b) Western blot was used to detect the protein expression of CCND1 in siCCND1 and siNC and a statistical histogram was shown at right (c). (d) CCK-8 assay was used to detect the HCT116 cell viability after the knockdown of CCND1. (e) A colony formation assay was used to detect the cell colony formation ability after the knockdown of CCND1 and a statistical histogram was shown at right (f). (g) Cell cycle distribution was measured by flow cytometry and a statistical histogram was shown at right (h). (i) Transwell assay was used to detect the invasion of HCT116 cells after knocking down CCND1 and a statistical histogram was shown at right (j). (k) The change in cell migration was examined by wound-healing assay in HCT116 cells after knocking down CCND1 and a statistical histogram was shown at right (l). *P < 0.05, **P < 0.01, and ***P < 0.001.
Figure 5: Overexpressed CCND1 could reverse the effects of let-7i-3p on HCT116 cells. (a) The level of CCND1 mRNA expression was detected by RT-PCR. (b) The level of CCND1 protein expression was detected by western blot and a statistical histogram was shown at right (c). (d) CCK-8 assay was used to explore the proliferation of HCT116 cells. (e) A colony formation assay was conducted to verify that ectopic CCND1 expression could reverse proliferation induced by let-7i-3p overexpression in HCT116 cells and a statistical histogram was shown at right (f). (g) Cell cycle distribution was measured by flow cytometry and a statistical histogram was shown at right (h). (i) Transwell assay was carried out to confirm the effects of CCND1 alteration in the invasion of HCT116 cells and a statistical histogram was shown at right (j). (k) The change in cell migration was examined by wound-healing assay in HCT116 cells and a statistical histogram was shown at right (l). *P < 0.05, **P < 0.01, and ***P < 0.001.
was significantly lower than that in FHC by qRT-PCR (Figure 1a). Based on bioinformatics software prediction and literature review, we attempted to detect the expression level of the target gene CCND1 in CRC cell lines and FHC. As expected, the result showed that CCND1 levels in CRC cell lines (HCT116, SW480, and LoVo) were significantly higher than that in FHC by qRT-PCR (Figure 1b).

Next, we demonstrated a role for let-7i-3p in the cell cycle, proliferation, invasion, and migration of HCT116 cells (Figure 2). Then, we performed a luciferase reporter assay to verify that CCND1 was a direct target of let-7i-3p (Figure 3). To elucidate the mechanism underlying the effects of let-7i-3p on proliferation, migration, and invasion, we tested whether CCND1 was required for the function of let-7i-3p by transfecting CCND1 siRNA into HCT116 cells. Likewise, silencing CCND1 inhibited the cell cycle, proliferation, invasion, and migration of HCT116 cells (Figure 4). Furthermore, ectopic expression of CCND1 offsets the inhibition of let-7i-3p overexpression on cell proliferation, migration, and invasion (Figure 5). These results suggested that CCND1 may act as a target of let-7i-3p and participate in the effect of let-7i-3p on the cell cycle, proliferation, migration, and invasion of CRC cells.

It is well known that the ERK signaling pathway plays an important role in several cellular processes, including cell cycle, proliferation, metastasis, survival, and apoptosis [22]. Leng et al. demonstrated that miR-29b suppressed the EMT and angiogenesis in CRC by disrupting the ETV4-dependent activation of the ERK signaling pathway [23]. Liu et al. revealed that miR-128-3p downregulated the deterioration rate of CRC by simultaneously silencing the activity of PI3K/AKT and MEK/ERK pathway [24]. Based on previous findings, we then investigated the effect of let-7i-3p and CCND1 on the regulation
of the ERK pathway. As demonstrated that overexpression of the let-7i-3p resulted in the inhibition of the p-ERK signal in HCT116 cells. Similarly, the same results can be obtained by downregulating the CCND1 expression by siRNA. In contrast, overexpression of CCND1 in the HCT116 cells led to the abnormal activation of the ERK pathway (Figure 6).

In summary, we reported a tumor suppressor for let-7i-3p in CRC progression. We showed that let-7i-3p inhibited cell cycle, proliferation, migration, and invasion in HCT116 cells. We also confirmed that let-7i-3p inhibited the ERK signaling activity through direct suppression of CCND1. Overall, we have identified the role and molecular mechanism of let-7i-3p in HCT116 cells, and let-7i-3p may be a potential target for CRC treatment in the future.

Acknowledgments: We would like to thank Qifa Li (Nanjing Agricultural University, China) for providing the pmirGLO Dual-Luciferase miRNA Target Expression Vector and pcDNA3.1 (+) vector.

Funding information: This work was financially supported by the National Natural Science Foundation of China (Grant No. 81671226), the Doctoral Scientific Research Foundation of Xinxiang Medical University (No. 505117), and the Science and technology project of Henan Province (No. 222102310513).

Author contributions: Conceptualization: Fei Tu, Qingzhi Wang, and Zhiwei Feng. Data curation: Fei Tu, Mengfan Li, Yinyu Chen, Huiru Chu, Ting Xie, and Fangfeng Geng. Funding acquisition: Fei Tu and Zhiwei Feng. Investigation: Fei Tu, Mengfan Li, Yinyu Chen, Huiru Chu, Ting Xie, Fangfeng Geng, and Tiesuo Zhao. Resources: Shujie Wang, Lun Hai, and Tiesuo Zhao. Supervision: Fei Tu, Qingzhi Wang, and Zhiwei Feng. Validation: Yinyu Chen, Huiru Chu, Shujie Wang, and Lun Hai. Writing – original draft: Fei Tu, Qingzhi Wang, and Zhiwei Feng. Writing – review and editing: Fei Tu, Qingzhi Wang, and Zhiwei Feng.

Conflict of interest: Authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014 Apr 26;383(9927):1490–502. doi: 10.1016/S0140-6736(13)61649-9.

[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.

[3] Valderrama-Treviño AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic metastasis from colorectal cancer. Euroasian J Hepatogastroenterol. 2017 Jul–Dec;7(2):166–75. doi: 10.5005/jp-journals-10018-3241. Epub 2017 Sep 29.

[4] Wang Y, Jiang F, Xiong Y, Qiu Z, Song R. LncRNA TTN-AS1 sponges miR-376a-3p to promote colorectal cancer progression via upregulating KLF15. Life Sci. 2020 Mar 1;244:116936. doi: 10.1016/j.lfs.2019.116936. Epub 2019 Oct 11.

[5] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 Jan 23;116(2):281–97. doi: 10.1016/s0092-8674(04)00045-5.

[6] Hultvågner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002 Sep 20;297(5589):2056–60. doi: 10.1126/science.1073827. Epub 2002 Aug 1.

[7] Zeng Y, Cullen BR. Sequence requirements for micro RNA processing and function in human cells. RNA. 2003 Jan;9(1):112–23. doi: 10.1216/rna.2780503.

[8] Min K, Lee SK. EBV miR-BART10-3p promotes cell proliferation and migration by targeting DKK1. Int J Biol Sci. 2019 Jan 24;15(3):657–67. doi: 10.7150/ijbs.30099.

[9] Borden A, Kurian J, Nickoloff E, Yang Y, Trpapes CD, Ibbet j, et al. Transient introduction of miR-29a in the heart promotes cardiomyocyte cell cycle reentry after injury. Circ Res. 2019 Jun 21;125(1):14–25. doi: 10.1161/CIRCRESAHA.118.314223. Epub 2019 Apr 9.

[10] Yang Y, Li W, Wei B, Wu K, Liu D, Zhu D, et al. MicroRNA let-7i inhibits histone lysine demethylase KDM5B to halt esophageal cancer progression. Mol Ther Nucleic Acids. 2020 Sep 16;22:846–61. doi: 10.1016/j.omtn.2020.09.012.

[11] Shi Y, Duan Z, Zhang X, Zhang X, Wang G, Li F. Down-regulation of the let-7i facilitates gastric cancer invasion and metastasis by targeting COL1A1. Protein Cell. 2019 Feb;10(2):143–8. doi: 10.1007/s13238-018-0550-7.

[12] Tang W, Zhou W, Xiang L, Wu X, Zhang P, Wang J, et al. The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer. Nat Commun. 2019 Feb 8;10(1):663. doi: 10.1038/s41467-018-08225-3.

[13] Pestell RG. New roles of cyclin D1. Am J Pathol. 2013 Jul;183(2):3–9. doi: 10.1016/j.ajpath.2013.03.001.

[14] Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, et al. Control of CCND1 ubiquitination by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9298–307. doi: 10.1073/pnas.1807704115. Epub 2018 Sep 17.

[15] Li Z, Li X, Li C, Su Y, Fang W, Zhong C, et al. Transcription factor OCT4 promotes cell cycle progression by regulating CCND1 expression in esophageal carcinoma. Cancer Lett. 2014 Nov 1;354(1):77–86. doi: 10.1016/j.canlet.2014.07.049. Epub 2014 Aug 12.

[16] Zhang Z, Li J, Huang Y, Peng W, Qian W, Gu J, et al. Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by...
directly targeting E2F8 in CRC. Cell Prolif. 2018 Dec;51(6):e12505. doi: 10.1111/cpr.12505. Epub 2018 Aug 24.

[17] Yu L, Ye F, Li YY, Zhan YZ, Liu Y, Yan HM, et al. Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis. Carcinogenesis. 2020 Jul 10;41(5):678–88. doi: 10.1093/carcin/bgz131.

[18] Zhou J, Liu H, Zhang L, Liu X, Zhang C, Wang Y, et al. DJ-1 promotes colorectal cancer progression through activating PLG12/Wnt/BMP4 axis. Cell Death Dis. 2018 Aug 29;9(9):865. doi: 10.1038/s41419-018-0883-4.

[19] Luo Y, Ge R, Wu H, Ding X, Song H, Ji H, et al. The osteogenic differentiation of human adipose-derived stem cells is regulated through the let-7i-3p/LEF1/β-catenin axis under cyclic strain. Stem Cell Res Ther. 2019 Nov 21;10(1):339. doi: 10.1186/s13287-019-1470-z.

[20] Sun S, Xu Y, Zhu Z, Kong D, Liu H, Zhou Z, et al. MicroRNA let-7i-3p affects osteoblast differentiation in ankylosing spondylitis via targeting PDK1. Cell Cycle. 2021 Jun;20(12):1209–19. doi: 10.1080/15384101.2021.1930680. Epub 2021 May 28.

[21] Falzone L, Lupo G, La Rosa GRM, Crimi S, Anfuso CD, Salemi R, et al. Identification of novel microRNAs and their diagnostic and prognostic significance in oral cancer. Cancers (Basel). 2019 Apr 30;11(5):610. doi: 10.3390/cancers11050610.

[22] Kidger AM, Sipthorp J, Cook SJ. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. Pharmacol Ther. 2018 Jul;187:45–60. doi: 10.1016/j.pharmthera.2018.02.007. Epub 2018 Feb 16.

[23] Leng Y, Chen Z, Ding H, Zhao X, Qin L, Pan Y. Overexpression of microRNA-29b inhibits epithelial-mesenchymal transition and angiogenesis of colorectal cancer through the ETV4/ERK/EGFR axis. Cancer Cell Int. 2021 Jan 6;21(1):17. doi: 10.1186/s12935-020-01700-2.

[24] Liu X, Dong C, Ma S, Wang Y, Lin T, Li Y, et al. Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway. Drug Deliv. 2020 Dec;27(1):323–33. doi: 10.1080/10717544.2020.1716882.